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The recent progress in our understanding of anti- 
body structure and biosynthesis - while along an 
adventurous and tortuous path - has been simply 
tremendous. Two symposia volumes have appeared 
recently (Nobel Symposia 3, on Gamma Globulins, 
ed. J.Killander; and Cold Spring Harbor Symposia on 
Quantitative Biology, Vol. 32, on Antibodies, 1967) 
which bear witness to this statement. To the bio- 
chemist it is of special interest to see how closely 
this progress follows the prediction of Svante Arr- 
henius given in 1906 in his book on “Immunochem- 
istry”, namely that he will not be surprised if studies 
on the structure and interactions of antibodies will 
help, in the final analysis, the elucidation of their 
biosynthesis. 
It is not intended to summarize here the many 
reports on amino acid sequence of light and heavy 
chains, mainly of myeloma immunoglobulins, nor 
to discuss the generalizations to which they led. 
Efforts to understand the genetic mechanisms under- 
lying the antibody formation have resulted in a 
burst of theories, some of them with a half-life 
shorter than the period elapsed between submission 
to press and publication. I would like to mention 
here three aspects of antibody structure. 
Seeing is believing! 
Electron microscopy can show the general struc- 
ture of immunoglobulins. This was indicated by 
several earlier studies, but demonstrated recently in 
a particularly elegant way by Valentine and Green 
(J. Mol. Biol. 27 (1967) 615, and the Nobel Sym- 
posium). Antibodies of the immunoglobulin G class 
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were cross-linked by a bifunctional happen to form 
closed rings with various symmetrical shapes 
(triangles, squares, pentagons, etc.). The authors 
conclude that the antibody molecule is clearly very 
flexible for such a wide range of different shapes to 
be formed. It was also noticed that each corner 
of the various figures contained a conspicuous pro- 
jection. After the preparation had been digested with 
pepsin, the regular shapes were still present but now 
without the projection. This identifies it as the Fe 
fragment of the molecule while the sides of the 
regular shapes must be the pepsin-resistant Fab frag- 
ments. They are linked at the centre of leach side by 
the divalent hapten and at the corners by the 
disulphide bond which joins the two Fab fragments 
of each molecule. The authors found in their pic- 
tures a maximum length for the Fab fragment of 
70 A, suggesting that antibody bridges between 
two antigenic sites should have a maximum stretch 
of 140 A. 
A good glimpse has also been obtained recently 
of the immunoglobulin M molecule (Hoglund, and 
Svehag et al., in the Nobel Symposium; Chesebro 
et al., J. Exp. Med. 127 (1968) 399). Svehag and 
his colleagues have shown that normal human and 
rabbit immunoglobulin M as well as Waldenstrom 
macroglobulins are indistinguishable from one 
another, when examined in the electron microscope, 
and reveal flexible spiderlike particles with five 
appendages joining a central ring. On the other hand, 
electron microscopy of reduced and alkylated 
immunoglobulin M revealed total absence of intact 
spider-like molecules. Thus, all the above studies 
show a beautiful agreement between chemical data 
and electron-microscopic pictures, and demonstrate 
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the usefulness of this tool in structural studies. 
How homogeneous can antibodies be? 
It has been stated again and again that an immuno- 
chemist must choose between working with 
heterogeneous immunoglobulins, known to combine 
immunospecifically with defined antigens, and 
working with homogeneous immunoglobulins devoid 
of known biological activities. Indeed, almost all 
the recent structural chemical studies were on 
myeloma immunoglobulins. 
Specific antibodies are commonly very heteroge- 
neous, and there are only a few instances in which 
more homogeneous populations were observed. 
Thus, relatively homogeneous anti-rhamnose anti- 
bodies were produced in abundance by certain New 
Zealand rabbits immunized with streptococci 
(Osterland et al., J. Exp. Med. 123 (1966) 599; 
Miller et al., J. Immunol. 98 (1967) 710). A restricted 
heterogeneity has been also reported for the light 
chains derived from antibodies associated with 
chronic cold agglutinin disease (Cohen, Nobel Sym- 
posium). These have affinity for the I antigen of the 
erythrocyte, and are almost always immunoglobulin 
M molecules with type K light chains. 
Against the above background, the report of 
Nisonoff et al. (Cold Spring Harbor) on crystalline 
immunospecifically purified antibody to the p- 
azobenzoate group seems particularly dramatic. The 
antibody, prepared from the serum of an individual 
rabbit, crystallized spontaneously from cold neutral 
buffer solution at a concentration of 60 mg/ml. The 
protein redissolved at 37O and recrystallized at 5O 
at much lower concentrations. As expected, the 
antibody seemed homogeneous both in disc electro- 
phoresis and with respect to combining affinity. The 
sense of drama is heightened by our being informed 
that the rabbit, from whose blood the antibody 
was isolated, is dead, and that - to our knowledge - 
no other rabbit has yet produced similarly crystal- 
lizable antibody. 
Another approach in attempts to reduce the 
heterogeneity of the antibody population has been 
to synthesize relatively simple and well defined 
antigens. Haber et al. (Cold Spring Harbor) have now 
reported that the energy of binding the hapten by 
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the anti-dinitrophenyl antibodies provoked in rabbit 
with an ordered sequence copolymer containing 
alanine and edinitrophenyllysine, did not change 
with time, in contrast to the usually described in- 
crease of the binding energy as a function of time. 
Again, immunization of rabbits with a branched 
polymer in which angiotensin was bound to poly- 
lysine, led to formation of antibodies monodisperse 
with respect to binding affinity. Thus, an appropriate 
reduction in the degree of heterogeneity of antigen 
may modify not only the temporal rise in the asso- 
ciation constants generally observed during the 
immune response, but also reduce the range of asso- 
ciation constants present in a given antibody. 
In view of the homogeneity of myeloma immuno- 
globulins, effectively studied only in man and in the 
mouse, it was natural that considerable effort should 
be spent on producing myeloma proteins with anti- 
body specificity as a result of immunization. All 
such efforts have failed until now. On the other hand, 
some myeloma proteins seem to be antibodies of 
low avidity against definable antigens (Zettervall 
et al., Clin. Exp. Immunol. 1 (1966) 213). More 
recently, a Waldenstrom macroglobulin was shown 
to have a well-defined specificity towards the Fc 
portion of human immunoglobulin G (Metzger, Proc. 
Natl. Acad. Sci. 57 (1967) 1490; Stone and Metzger, 
Cold Spring Harbor). 
In the same Cold Spring Harbor symposium 
volume M.Cohn describes one mouse myeloma 
which produced an antibody directed against the C- 
polysaccharide of the pneumococcus, whereas 
Eisen et al. report a human myeloma protein with 
anti-2,4-dinitrophenyl activity. Using a simple 
procedure, based on a spectral shift upon reacting 
e-dinitrophenyl-Llysine with anti-dinitrophenyl 
antibody, Eisen et al. screened eightyeight sera 
from patients with multiple myeloma, and thus 
detected the anti-dinitrophenyl myeloma immuno- 
globulin. Its affinity for the ligand was low 
(2.3 X lo4 M-l), and its specificity resembled the 
low affinity anti-dinitrophenyl antibodies that 
appear in rabbit serum shortly after immunization 
is initiated. 
This interesting finding raises many hopes, as we 
have here a molecule closest to a homogeneous 
antibody, but it also presents many puzzles. Is 
every hundredth myeloma protein an anti-dinitro- 
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phenyl antibody? What is the frequency of the various 
specificities? How specific is “specific” in this con- 
text? And finally - in the discussion of the persisten- 
ce of the antigen (or hapten) in the cells producing 
antibodies - do we really expect to find some 
dinitrophenyl groups in the cells producing that par- 
ticular myeloma globulin? One does not have to be a 
far-reaching prophet to expect many more reports 
about the detection of antibody activities in mye- 
loma proteins in the near future, be they due to 
serendipity, clever screening schemes, or - simply - 
a considerable expenditure of routine labour. 
Valency of macroantibodies: five or ten? 
A typical immunoglobulin G antibody is divalent, 
i.e. it has two sites capable of combining with anti- 
genie determinants. As immunoglobulin M (the 
macroglobulin) is composed of five subunits, each of 
a size comparable to that of immunoglobulin G 
(Miller and Metzger, J. Biol. Chem. 240 (1965) 3325; 
Lamm and Small, Biochemistry 5 (1966) 267), it 
might be expected that a macroglobulin antibody 
would have ten combining sites per molecule - if 
each subunit is divalent, or five combining sites - if 
the macroglobulin subunits are monovalent. Onoue 
et al. (Immunochemistry 2 (1965) 40 1) have found 
that rabbit macroantibodies against the p-azoben- 
zenearsonate group bound only one p-iodobenzene- 
arsonate per two heavy-light polypeptide chain pairs. 
Essentially no change in the number of binding 
sites was observed upon dissociation of the 
immunoglobulin M antibody into its subunits by mild 
reduction and alkylation. Thus, the isolated subunits 
seem to be univalent, notwithstanding the structural 
evidence which is overwhelmingly in favor of a 
divalent subunit. 
In contrast to the above finding, Stone and Metz- 
ger (Cold Spring Harbor) observed that almost all 
the Fab fractions isolated from their Waldenstrom 
macroglobulin antibody were able to bind to “antigen” 
(in this case, human immunoglobulin G). Similarly, 
Merler et al. (J. Biol. Chem. 243 (1968) 386) reported 
that the human macroantibody to a Salmonella typhi 
0 antigen had ten antigen-combining sites per mole- 
cule. Their conclusion was based on equilibrium 
dialysis studies of the purified macroantibodies with 
a tetrasaccharide isolated after partial hydrolysis 
from the lipopolysaccharide of S. typhi. The authors 
followed the concentration of the tetrasaccharide by 
absorption at 210 nm, which may be a major experi- 
mental difficulty. 
Last May two additional studies on macroantibody 
subunits have appeared. Schrohenloher and Barry 
(J. Immunol. 100 (1968) 1006) investigated in the 
ultracentrifuge the reaction of human immuno- 
globulin G with subunits derived from immuno- 
globulin M anti-y-globulins (rheumatoid factors), 
and found that the compositions of the soluble com- 
plexes formed were not altered by varying the ratio 
of the reactants. One immunoglobulin M subunit 
bound about one immunoglobulin G molecule. If 
the last one may be considered as a univalent antigen, 
the conclusion would be drawn that the macroanti- 
body subunit is monovalent. 
Frank and Humphrey (J. Exp. Med. 127 (1968) 
967) have now reported a detailed study of the sub- 
units in rabbit anti-Forssman macroantibody. The 
Forssman antigen is a heterogenetic antigen con- 
taining determinants, probably of mucopoly- 
saccharide nature, common to red cells of different 
species, and related also to some bacterial antigens. 
Working at very low concentrations of antibody, 
Frank and fiumphrey have obtained on mild reduc- 
tion subunits which appear to be composed of a 
single heavy and light chain. Only half of these sub- 
units could be shown to have specific binding sites 
for Forssman antigen. Thus, the data are consistent 
with the concept that each anti-Forssman immuno- 
globulin M molecule has five effective binding sites. 
At this stage, the particular problem of macro- 
antibody valency is in a state of healthy confusion, 
though undoubtedly it will be solved in the near 
future. From this point of view, it resembles many 
other problems of central interest in immunochem- 
istry. 
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